Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyavalon_healthcare_solutions urinary tumor markers …
    Ask Trek AI about this page
    Currentavalon_healthcare_solutionsPolicy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer

    Urinary Tumor Markers for Bladder Cancer

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer alerts

    Get alerted when Policy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage stance and clinical indications/limitations for urinary tumor marker tests (e.g., BTA, NMP22, UroVysion, ImmunoCyt, and other urinary biomarker assays) for diagnosis and surveillance of bladder cancer for Avalon Healthcare Solutions members.

    Policy Summary
    Payeravalon_healthcare_solutions
    PolicyUrinary Tumor Markers for Bladder Cancer
    Policy CodePolicy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewOct 31, 2025
    Next Review DateOct 21, 2025
    Key ActionDocument that urinary biomarker testing is being used only as an adjunct for atypical/equivocal cytology or for monitoring high-risk non‑muscle invasive bladder cancer and provide supporting clinical justification.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 situationsCovered adjunct uses
    Screening/hematuria/diagnosisExcluded indications
    MultipleTests discussed
    $25–$800Estimated costs

    Coverage Determinations and Criteria

    inv-01: Covered indications (adjunct uses)

    Covered when ANY of the following adjunct indications apply:

    Covered adjunct uses: 1) Urinary biomarkers (bladder tumor antigen [BTA], nuclear matrix protein 22 [NMP22], or fluorescence in situ hybridization [FISH] UroVysion) as an adjunct in the diagnostic exclusion of bladder cancer for individuals who have an atypical or equivocal cytology.

    Exact tests named: BTA, NMP22, UroVysion (FISH).

    Covered adjunct uses: 2) Urinary biomarkers (BTA, NMP22, or UroVysion [FISH]) as an adjunct in the monitoring of high-risk, non–muscle‑invasive bladder cancer (surveillance).

    Exact tests named: BTA, NMP22, UroVysion (FISH).

    Covered adjunct uses: 3) Fluorescence immunocytology (ImmunoCyt/uCyt+) used as an adjunct to cystoscopy or cytology in the monitoring of individuals with bladder cancer.

    Exact test named: ImmunoCyt/uCyt+.

    inv-02: Not medically necessary / Excluded indications

    Not covered (do not meet coverage criteria):

    Not covered uses: Use of urinary biomarkers (BTA, NMP22, UroVysion [FISH]) or ImmunoCyt/uCyt+ for evaluation of hematuria; for screening for bladder cancer in asymptomatic individuals; to diagnose bladder cancer in symptomatic individuals; or for any other indication not explicitly listed as covered.

    Policy cites lack of published scientific literature supporting these broader uses.

    Not covered uses: Any other urinary tumor markers for bladder cancer not mentioned in this policy do not meet coverage criteria (considered not medically necessary).

    Tests not listed in policy are explicitly excluded.

    inv-03: Coverage context and conditional utility

    Coverage stance and clinical criteria context summarized from evidence and guideline sections:

    Adjunctive use consistent with guidelines: Urinary tumor markers may be considered only as adjuncts to cystoscopy for surveillance of high‑risk non‑muscle‑invasive bladder cancer and for adjudication of equivocal cytology; they should not replace cystoscopy for diagnosis or routine surveillance.

    Supported by NCCN (category 2B), AUA/SUO, and EAU guidance.

    Markers with conditional utility: Some multi‑target and proprietary assays (for example, CxBladder, Oncuria, EpiCheck and other multi‑target tests) have reported high sensitivity and negative predictive value for high‑grade disease in selected studies; these findings are heterogeneous, sometimes vendor‑funded, and may support selective adjunctive use to help rule out high‑grade recurrence when aligned with clinical judgment and surveillance strategy.

    Evidence includes meta‑analyses and single‑study performance metrics showing variable sensitivity/specificity and higher performance for higher‑grade tumors.

    Limitations for screening and low‑grade disease: Urinary biomarkers have lower accuracy for low‑stage/low‑grade tumors, produce false positives, and are not supported for population screening or routine evaluation of asymptomatic microhematuria; performance degrades in low‑prevalence screening settings.

    Urinary biomarkers, including bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22), fluorescence in situ hybridization (UroVysion), and ImmunoCyt/uCyt, do not meet coverage criteria when used for the evaluation of hematuria, for screening asymptomatic individuals for bladder cancer, to diagnose bladder cancer in symptomatic individuals, or for any other indication not explicitly listed as covered in this policy.

    Major clinical guidelines do not support replacing cystoscopy with urinary biomarker testing. The NCCN recommends that urine molecular tests may be considered during surveillance of high‑risk non–muscle‑invasive bladder cancer but states that testing should not replace cystoscopy and should be used in tandem with cystoscopic evaluation; AUA guidance similarly advises that urine‑based tumor markers are not a substitute for cystoscopy in diagnosis or routine surveillance.

    The FDA has approved ImmunoCyt as a qualitative direct immunofluorescence assay only as an aid in surveillance—to be used in conjunction with urinary cytology and cystoscopy for management of patients previously diagnosed with bladder cancer. ImmunoCyt is not FDA‑approved for initial diagnostic use.

    Any urinary tumor markers for bladder cancer not specifically mentioned in this policy are considered not medically necessary and do not meet coverage criteria.

    Routine population screening for bladder cancer in asymptomatic adults is not supported by the evidence and guideline bodies (USPSTF, AUA, NCI) and therefore is not covered. Similarly, the routine use of urine tumor markers in the initial evaluation of microhematuria is not recommended and does not meet coverage criteria; markers have not demonstrated sufficient incremental value to obviate cystoscopy in this setting.

    Procedure Codes and Billing References

    Procedure codes (referenced)mixed
    affected codesPolicy references 'APPLICABLE CPT/HCPCS PROCEDURE CODES' section (codes not included in this partial document).
    Procedure code referencemixed
    Procedure codes are listed in policy documents for reference; not all-inclusive and subject to updates.
    Common lab CPT CodesCPT
    86294Immunoassay for tumor antigen, qualitative or semiquantitative (eg, bladder tumor antigen).
    86316Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549), each.
    86386Nuclear Matrix Protein 22 (NMP22), qualitative.
    Cytopathology / FISHCPT
    88346Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; manual.
    88350Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; using computer-assisted technology.
    PLA / Proprietary molecular assay codesHCPCS
    0363UOncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma. Proprietary test: Cxbladder Detect.
    0365UOncology (bladder), analysis of 10 protein biomarkers by immunoassays, urine, probability of harboring urothelial bladder cancer. Proprietary test: Oncuria Detect.
    0366UOncology (bladder), analysis of 10 protein biomarkers by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer. Proprietary test: Oncuria Monitor.
    0367UOncology (bladder), analysis of 10 protein biomarkers by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence/recurrent or persistent cancer following transurethral resection. Proprietary test: Oncuria Predict.
    0420UOncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with ddPCR analysis of TERT and FGFR3 SNPs, urine, algorithm reported as a risk score. Proprietary test: Cxbladder Detect (PLA/variant).
    0452UOncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative. Proprietary test: EarlyTect BCD.
    0465UOncology (urothelial), DNA, quantitative methylated real-time PCR of TRNA-Cys, SIM2, and NKX1-1, urine, diagnostic algorithm reported as a probability index for bladder cancer/UTUC. Proprietary test: Bladder CARE.
    0549UCode added to policy (description updated in policy).

    Provider Responsibilities, Documentation, and Billing Guidance

    Prior Authorization

    Coverage limited to specified adjunct uses

    Urinary biomarker tests (BTA, NMP22, UroVysion, ImmunoCyt, and other urinary tumor markers listed in this policy) are covered ONLY as adjunctive tests in the specific situations listed in the policy; requests for use outside those adjunct indications do not meet coverage criteria and may be denied.

    • Covered adjunct uses: (a) adjunct in diagnostic exclusion for individuals with atypical or equivocal cytology; (b) adjunct in monitoring high‑risk, non‑muscle invasive bladder cancer; (c) ImmunoCyt/uCyt as an adjunct to cystoscopy or cytology for monitoring.
    Billing Rule

    Billing/authorization reference — codes are reference only

    Procedure and HCPCS/CPT codes in this policy are provided for reference only; listing of a procedure code does not guarantee payment—verify payer billing rules and plan contract for authorization and payment requirements.

    Clinical Background and Evidence Summary

    Bladder cancer most commonly arises from the urothelium and frequently presents with hematuria. Cystoscopy (white‑light cystoscopy) with cytology remains the diagnostic gold standard for detection and surveillance, and urinary tumor markers have generally been developed to serve as adjuncts to, rather than replacements for, cystoscopic evaluation.

    Test Definitions and Abbreviations

    BTA — Bladder Tumor Antigen
    DefinitionBTA (Bladder Tumor Antigen) detects complement factor H–related protein (hCFHrp).
    Assay formatsAvailable in both qualitative (BTA stat®) and quantitative (BTA TRAK®) assays.
    Manufacturer-recommended cut-offBTA manufacturer-recommended cut-off reported as 14 U/mL.
    NMP22 — Nuclear Matrix Protein 22
    DefinitionNMP22 (Nuclear Matrix Protein 22) is a urinary protein marker released by cancer cells following apoptosis.
    Assay formatsAvailable in quantitative (e.g., Matritech NMP22 Test Kit) and qualitative formats (e.g., NMP22 BladderChek).

    Policy Updates and Approval History

    2025-10-31ODM approval and committee reviewLatest

    ODM approved policy updates; background, guidelines, and scientific references were updated without changes to coverage criteria; committee approved 10/27/2025 (OH FIDE).

    2025-10-23ODM approval

    ODM approved policy following OH MyCare FIDE Implementation Committee approval on 10/07/2025.

    2025-10-21ODM approval and committee update
    Policy Summary
    Payeravalon_healthcare_solutions
    PolicyUrinary Tumor Markers for Bladder Cancer
    Policy CodePolicy AHS - G2125 - Urinary Tumor Markers for Bladder Cancer
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewOct 31, 2025
    Next Review DateOct 21, 2025
    Key ActionDocument that urinary biomarker testing is being used only as an adjunct for atypical/equivocal cytology or for monitoring high-risk non‑muscle invasive bladder cancer and provide supporting clinical justification.
    SourceLink
    On This Page
    Coverage Determinations and CriteriaProcedure Codes and Billing ReferencesProvider Responsibilities, Documentation, and Billing GuidanceClinical Background and Evidence SummaryTest Definitions and AbbreviationsPolicy Updates and Approval History

    Referenced systematic reviews and guideline recommendations (AUA, USPSTF) advise against routine screening or use in initial microhematuria evaluation.

    LDTs and regulatory context: Laboratory‑developed tests (LDTs) require CLIA validation and internal performance documentation; select assays have FDA approval/clearance with indications generally as adjuncts to cystoscopy or for surveillance rather than as standalone diagnostic replacements.

    Policy summarizes FDA approvals (e.g., UroVysion, ImmunoCyt) and CLIA/LDT requirements.

    • Refer to the member's Evidence of Coverage/plan contract and payer billing rules for authorization/payment decisions.
    Prior Authorization

    Procedure codes may require verification / prior authorization

    Procedure codes for urinary tumor marker tests (including CPT and PLA/HCPCS codes listed in the policy) may require verification of coverage and prior authorization per the member's plan or payer rules; coverage/payment is subject to policy rules and updates.

    • Examples of codes listed in the policy include 86294, 86386, 88346, 88350 and PLA/0363U–0549U series; providers should verify PA requirements for the specific code/test prior to ordering.
    Step Therapy

    Adjunct to cystoscopy — do not replace cystoscopy

    Cystoscopy with cytology remains the diagnostic gold standard for bladder cancer; urinary biomarkers are intended to be used adjunctively and not as replacements for cystoscopic diagnosis.

    • Use biomarkers in conjunction with cystoscopy and cytology per guideline recommendations.
    Step Therapy

    Adjunctive use before replacement — follow guideline expectations

    Clinical guidelines recommend urinary tumor markers should not replace cystoscopy; when used, markers are adjunctive and should not be the sole method prior to omitting or replacing cystoscopic evaluation.

    • NCCN and AUA/SUO guidance state markers may be considered during surveillance but should not replace cystoscopy.
    Note

    Adjunctive use only — avoid requests that imply replacement

    Tests are covered only as adjuncts and not as standalone replacements; do not submit requests that imply use of urinary tumor markers as primary diagnostic replacement for cystoscopy.

    • Orders implying a replacement of cystoscopy or standalone diagnostic use outside covered adjunct indications may be denied.
    Documentation Required

    Clinical indication documentation required

    Document the clinical indication in the medical record showing that testing is being used as an adjunct (e.g., atypical/equivocal cytology or monitoring high‑risk NMIBC); absence of supporting documentation for an adjunct indication risks denial.

    • State the specific adjunct rationale (atypical/equivocal cytology; high‑risk NMIBC surveillance) in the order/medical record.
    Documentation Required

    LDT validation documentation required (CLIA high‑complexity)

    Laboratory‑developed tests (LDTs) must be validated and performed in‑house under CLIA; provide documentation of CLIA high‑complexity validation and internal performance characteristics when ordering/claiming LDTs.

    • Include evidence of CLIA regulation and internal validation when the test is an LDT; note that LDTs are not FDA‑cleared/approved.
    Documentation Required

    Document intended FDA‑indicated use for specific assays

    When ordering FDA‑approved assays (for example, UroVysion or ImmunoCyt), document the intended FDA‑indicated use in the clinical record (e.g., ImmunoCyt is indicated as an aid in surveillance in conjunction with cytology and cystoscopy).

    • Record the assay name and that the intended use aligns with the FDA‑approved indication (diagnosis vs surveillance) in the chart.
    Denial Risk

    Denied indications — hematuria, screening, diagnostic use outside listed indications

    Requests for urinary biomarker testing for hematuria evaluation, population screening of asymptomatic individuals, diagnosis in symptomatic individuals, or any indication not explicitly listed in the policy do NOT meet coverage criteria and are at high risk for denial.

    • Explicitly excluded: evaluation of hematuria, screening asymptomatic individuals, diagnosing symptomatic patients, and any other non‑listed indications.
    Denial Risk

    Defer to applicable government coverage (LCD/NCD); conflicts may lead to denial

    If there is any conflict between this policy and an applicable government (Medicare/Medicaid) coverage determination (LCD/NCD or state Medicaid policy), the government policy controls; noncompliance with such government rules may result in denial.

    • Verify applicable LCDs/NCDs or state Medicaid rules for the member before ordering/testing.
    Billing Rule

    Code listing is not a guarantee of payment

    Procedure and CPT/HCPCS codes listed in this policy are provided as a reference and are not a guarantee of payment; the list may not be all‑inclusive and is subject to updates.

    • Providers must confirm code applicability and payer reimbursement policy; listing a code in this document does not ensure coverage.
    FDA cut-off
    FDA‑approved cut-off for NMP22 reported as 10 U/mL.
    UroVysion (FISH)
    DefinitionUroVysion is a fluorescence in situ hybridization (FISH) assay that detects chromosomal alterations associated with bladder cancer.
    TargetsDetects aneuploidy of chromosomes 3, 7, and 17 and loss of the 9p21 locus.
    Regulatory statusFDA-approved for detection of these chromosomal abnormalities in urine specimens.
    ImmunoCyt / uCyt+
    DefinitionImmunoCyt (uCyt+) is a fluorescence immunocytology test that detects cancer‑associated glycoproteins on exfoliated urothelial cells.
    Intended useIndicated as an aid in surveillance, used in conjunction with cytology and cystoscopy to increase overall sensitivity for detection of tumor cells in patients previously diagnosed with bladder cancer.
    Regulatory statusFDA-approved (qualitative direct immunofluorescence assay).
    LDT — Laboratory‑Developed Test
    DefinitionLaboratory‑Developed Test (LDT): a test developed and performed within a single laboratory and regulated under CLIA as a high‑complexity test.
    Regulatory noteLDTs are validated and performed in‑house and are not approved/cleared by the FDA; CMS regulates them under CLIA '88.
    Documentation expectationDocumentation of CLIA high‑complexity validation and internal performance is expected when ordering LDTs.
    Adjunctive testing — Definition and intended role
    DefinitionAdjunctive tumor marker testing: use of urine molecular or cytologic tests in combination with cystoscopy for surveillance or diagnostic adjudication of non‑muscle‑invasive bladder cancer (NMIBC).
    Clinical rolePositioned as an adjunct to — not a replacement for — cystoscopy; may be used to adjudicate equivocal cytology or monitor high‑risk NMIBC per guideline recommendations.
    LimitationsNot supported for routine population screening, initial evaluation of hematuria, or as a standalone diagnostic replacement for cystoscopy.
    UroVysion Bladder Cancer Kit
    Test nameUroVysion Bladder Cancer Kit.
    Assay purposeDesigned to detect aneuploidy for chromosomes 3, 7, and 17 and loss of the 9p21 locus via FISH in urine specimens.
    FDA statusFDA‑approved (UroVysion Bladder Cancer Kit approved January 24, 2005).
    ImmunoCyt — FDA‑approved indication
    Test nameImmunoCyt (uCyt+).
    Intended useQualitative direct immunofluorescence assay indicated as an aid in surveillance when used with cytology and cystoscopy for patients previously diagnosed with bladder cancer.
    Regulatory noteFDA‑approved (approved February 23, 2000) and indicated for use in conjunction with cytology and cystoscopy.

    ODM approved updates to background, guidelines, and evidence-based references; added CPT codes 0549U, 0452U, 0465U and updated description for CPT code 0365U; committee approved 05/21/2025 (OH MCD).

    2024-05-23ODM approval and literature review

    Reviewed and updated background, guidelines, and evidence-based references; literature review did not require changes to coverage criteria; committee approved 05/14/2024.

    2023-09-18Committee approval and code additions

    Committee approved policy updates after adding PLA codes 0363U, 0365U, 0366U, 0367U (0365U/0366U/0367U effective 04/01/2023); ODM approved 09/07/2023.

    2022-09-14Code updates

    Revised code disclaimer statement and added CPT codes 88346 and 88350.

    2021-07-01Initial effective date

    Policy initial effective date and summary of changes recorded.